Keywords
Acne vulgaris, hormone
Acne vulgaris, hormone
In the new version, we added detailed information about the included criteria. We also described the protocol of endocrine evaluation. And we put notes of abbreviations at the bottom of each table.
See the authors' detailed response to the review by Berna Aksoy
See the authors' detailed response to the review by Jerry Tan
See the authors' detailed response to the review by Mohamed Badawy Hassan Tawfik Abdel-Naser
Acne is a chronic inflammatory disorder of the pilosebaceous unit with various manifestations, including non-inflammation and inflammation lesions. Collier et al. (2008) investigated 1013 Americans aged 20 years and older; 73.3% (744) reported ever having acne, and more women suffer from acne than men.1 Four major factors involved in acne pathogenesis are excessive sebum production, follicular hyperkeratinization, hyper-colonization of the duct by Cutibacterium acnes (formerly Propionibacterium acnes), and the production of inflammation.2 Moreover, the hormone plays a part role in the pathogenesis of acne. Some studies found that acne had a relationship with hyperandrogenemia in female patients.3 Estradiol, the primary female sex hormone known as the major active estrogen, forms in absolute serum levels and estrogenic activity during human female reproductive years. Supplying sufficient amounts of estrogens will decrease sebum production and may act by suppressing androgen production by inhibiting the pituitary from secreting gonadotropin.4 The effect of progesterone on sebaceous glands was still disputed. Some authors have blamed progesterone for the change in sebum production in females during the menstrual cycle. However, this theory has not been proved experimentally.5 Therefore, we conducted this study to evaluate the serum testosterone, estradiol, and progesterone levels and the correlation of hormonal alterations with the severity of acne in women with acne vulgaris.
The cross-sectional study was conducted on 175 female patients diagnosed with acne vulgaris and 35 age-matched healthy females. Patients were recruited from the clinic of the Dermatology department, 103 military hospital, Vietnam, from January to October 2019. Approval was obtained from the ethics committee of the Hanoi Department of Science and Technology. Written informed consent for publication of the patients’ details was obtained from the patients.
We selected female acne patients aged between 16 and 25 who had not received drugs causing acne (glucocorticoids, lithium, isoniazid, phenytoin, selective reuptake serotonin inhibitors) or hormonal therapy (hormonal contraceptive and anti-androgen therapy) for at least three months before joining the study. Age-matched healthy volunteers without acne, pregnancy, or lactation served as the control group. None of the participants had been treated with hormonal treatment at this time of the study. All patients of each group were asked about history taken, throughout local and general clinical examinations to rule out any suspected similar diagnosis or other local and systemic disorders which contraindicate the patients from participating in this study. PCOS was also excluded by the manifestation of hyperandrogenism (hirsutism, oligomenorrhea) and confirmed with transvaginal and pelvic ultrasound.
Acne severity grading: The severity of acne was determined according to the Global Acne Grading System (GAGS).6 Each type of acneiform lesion has a gravity score: no lesions: 0; comedones: 1; papules: 2; pustules: 3; and nodules: 4. The local score was calculated using factor × grade 0-4. Depending on the acne lesion location, the factor had the following values: forehead: 2; right cheek: 2; left cheek: 2; chin: 1; thorax and upper torso: 1. The sum of the local scores was the global score which settled acne severity. In our study, a global score of 1-18 signified mild acne, 19-30 was moderate acne, and a global score > 31 was severe acne.
Endocrine evaluation: Each patient performed a hormonal profile, including testosterone, estradiol, and progesterone. Blood samples were collected at 08:00 am on the second to the fourth day of menses (the follicular phase of the menstrual cycle). Each 4 mL of venous blood was centrifuged and serum stored at -20°C. Hormone levels were measured by using direct chemiluminescent technology in the Unicel ® DXI800 machine. Units: testosterone for ng/dL, estradiol for pmol/L, progesterone for ng/mL. Women’s testosterone normal levels were considered as ≤0.86 ng/mL; estradiol ranged from 74–532 pmol/L; progesterone was ≤1 ng/mL.
The data were analyzed by SPSS software version 22.0. Mean SD is in the form: ±SD, comparing two means using the student t-test. The research results were compared by the Chi-squared test. P values of less than 0.05 were considered to be significant.
Two hundred and ten female participants were enrolled in the study and divided into 175 female patients with acne vulgaris and 35 healthy controls. The mean age of patients for the acne group was 20.82±2.53 years, and for the controls, it was 19.91±2.57 years ranging from 18 to 25 years (Table 1).
Age and BMI features of acne vulgaris group and control group.
Characteristics | Acne group (n=175) | Control group (n=35) | p-value | Normal range |
---|---|---|---|---|
Average age (years) | 20.82±2.53 | 19.91±2.57 | >0.05 | |
BMI (kg/m2) | 19.33±1.51 | 18.90±1.62 | >0.05 | 18.5–24.9 |
The serum hormone levels between both groups are shown in Table 2. The plasma testosterone level of the acne vulgaris patients was significantly higher than the control group (55.67±25.56 ng/dL, 38.37±10.16 ng/dL, respectively). On the other hand, plasma estradiol level in acne vulgaris patients was lower than in the control group (p<0.05). However, plasma progesterone levels were not different between both groups.
Plasma hormone levels of acne vulgaris group and control group.
Characteristics | Acne group (n=175) | Control group (n=35) | p-value | Normal range |
---|---|---|---|---|
Testosterone (ng/dL) | 55.67±25.56 | 38.37±10.16 | <0.05* | 6–86 |
Estradiol (pmol/L) | 323.15±93.31 | 370.94±58.88 | <0.05* | 74–532 |
Progesterone (ng/mL) | 0.60±0.38 | 0.50±0.15 | >0.05 | <1 |
Regarding the hormonal alteration proportion, fifty-two patients (29.7%) out of 175 acne patients had hormonal alterations, including 28 patients (16%) with hyperandrogenism; 20 patients (11.43%) had increased serum progesterone levels, only four patients (2.29%) had increased serum estradiol level, and no patient had low hormonal levels as shown in Table 3.
Hormonal alterations in female acne patients.
Value | Testosterone | Estradiol | Progesterone | Total (n=175) |
---|---|---|---|---|
Normal | 147 (84.0%) | 171 (97.71%) | 155 (88.57%) | 124 |
Increase | 28 (16.0%) | 4 (2.29%) | 20 (11.43%) | 52 (29.7%) |
Decrease | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
In terms of the relationship between serum hormone levels and acne severity, we found no different hormone levels between the grades of the acne vulgaris group. However, testosterone levels in moderate and severe groups were statistically significantly higher than in the control group. Estradiol levels in the moderate and severe groups were statistically significantly lower than in the controls (p<0.05). Progesterone levels in the mild and moderate groups were similar to the control group, except in the severe group. These differences are shown in Table 4.
Plasma hormone levels in severity groups of acne patients.
Hormone | Acne vulgaris group | Control group (4) | p-value | ||
---|---|---|---|---|---|
Mild (1) | Moderate (2) | Severe (3) | |||
Testosterone (ng/dL) | 43.06±14.76 | 56.92±27.64 | 60.71±25.85 | 38.37±10.16 | p 1,4>0.05 p 2,4<0.05* p 3,4<0.05* |
p>0.05 | |||||
Estradiol (pmol/L) | 354.97±108.46 | 325.13±91.79 | 305.26±83.0 | 370.94±58.88 | p 1,4>0.05 p 2,4<0.05* p 3,4<0.05* |
p>0.05 | |||||
Progesterone (ng/mL) | 0.52± 0.32 | 0.59 ± 0.39 | 0.65±0.40 | 0.50 ± 0.15 | p 1,4>0.05 p 2,4>0.05 p 3,4<0.05* |
p>0.05 |
In this study, the median age in the acne groups was 20.82±2.53 years, younger than the previous study, with a mean of 26.64 years.5
In literature reviews, authors conducted studies to determine the relationship between serum hormone levels and acne. However, the results were not consistent. In 2013, da Cunha et al. investigated 835 female patients with acne vulgaris and found that 56.52% of cases changed at least one androgen hormone, and DHEAS levels were the most frequently increased.5 In this study, we found that the rate of changing hormone levels in female patients with acne vulgaris was 29.14%.
Androgens play a crucial role in acne pathogenesis. Androgens increase sebum production and increase the keratinization process around the neck of hair follicles, facilitating the formation of acne. In the study by Cunha et al., the authors found that the rate of androgenism was 10.77%.5 In 2014, Wei et al. found that serum testosterone levels were significantly increased in the acne patient group compared with controls.7 In this study, the testosterone level of the acne group was higher than controls, and the hyperandrogenism rate was 16%. This result was also consistent with the study by Bakry et al.2 However, in the study by Cetinozman8 and Akdogan,9 no significant change in testosterone levels was found between the acne and control groups. The discrepancy among the research results can be explained that the numbers of samples of the previous authors were not large enough, and the method of grading the severity of acne disease between the studies was based on different scales. Furthermore, anti-androgen therapy improved acne lesions in patients with polycystic ovary syndrome,10 which shows the critical role of androgen in the pathogenesis of acne.
We hypothesize that estrogens might impact sebum secretion by three different mechanisms: the opposition of androgens within the sebaceous glands, inhibition of gonadal androgen production via a negative feedback mechanism on gonadotropin release, and affects genes that play a role in sebaceous gland growth and lipid production.11 Wei et al. surveyed 118 female acne patients compared with 90 sex-matched controls. The results showed that the estradiol level in the acne group decreased significantly compared with the control group.7 This result was also consistent with our result.
Testosterone is converted into a more potent form DHT by 5-ARD (5α-reductase) enzyme causing an excess sebum production, whereas progesterone inhibits the activity of this enzyme and prevents turning testosterone into DHT. So, progesterone itself might be expected to reduce sebaceous gland activity. However, the progesterone effect on acne remains unclear. Although some studies show that progesterone can reduce androgen effects by inhibiting the 5-ARD enzyme or androgen receptors,12 the fluctuation of sebum production in women during the menstrual cycle and premenstrual cyclic flare has partly been associated with progesterone, and some progestins lead to an exacerbation of acne by interacting with androgen receptors.12,13 In our study, there was no statically significant difference between the acne group and controls in terms of serum progesterone levels. However, the progesterone level of the severe acne was higher than the control group. In the study by Bakry et al., the progesterone levels in female acne patients were higher than those in the control group.2 It was similar to the study by Arora et al.14 The difference in results between our study and other studies can be explained by the different days of hormone tests in the menstrual cycle and different inclusion criteria. Arora14 and Bakry2 investigated plasma hormones during the luteal phase of menses. Meanwhile, we performed in the follicular phase of menses.
There was no significant correlation of testosterone, estradiol, and progesterone levels with severity with Spearman Correlation (Table 4). In the study by Kiaynai et al., there was no positive correlation between testosterone plasma levels and the severity of acne.15 Skrgatic et al. reported similar results when investigating Croatian females of reproductive age.16 In contrast, Rehman et al. found a correlation between acne severity and plasma testosterone levels.17 However, these studies were based on small sample sizes and excluded patients with mild acne with no hyperandrogenism and selected patients with severe comedones, severe inflammatory and/or purulent papules, and mild acne patients with hyperandrogenism.
This study showed that female acne vulgaris patients might have high serum testosterone levels and low serum estradiol levels compared with those of female controls. However, hormone levels differences had no correlation with acne grade.
Dryad: Underlying data for ‘Assessment of serum hormone levels in female patients with acne vulgaris’. https://doi.org/10.5061/dryad.bvq83bk9z18
The project contains the following underlying data:
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Approval was obtained from the ethics committee of Hanoi Department of Science and Technology with the code: 01C-08/14-2017-3. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
Written informed consent for publication of the patients’ details was obtained from the patients.
The authors would like to thank the Department of Dermatology and Venereology of 103 Military hospital, Military Medical University, for their support during the study and the patients for their voluntary participation in this research.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
No
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
No
References
1. Hedayat K, Lapraz J: Acne: Disorder of luteal androgen management. 2019. 165-183 Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Acne, pigmentary disorders
Is the work clearly and accurately presented and does it cite the current literature?
No
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
No
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
No
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Acne
Competing Interests: No competing interests were disclosed.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
No
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Acne
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||||
---|---|---|---|---|
1 | 2 | 3 | 4 | |
Version 5 (revision) 19 Jan 23 |
read | |||
Version 4 (revision) 22 Apr 22 |
read | |||
Version 3 (revision) 04 Apr 22 |
||||
Version 2 (revision) 09 Feb 22 |
read | read | ||
Version 1 11 Jan 22 |
read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)